Efficacy and Safety of Interventions to Control Myopia Progression in Children: An Overview of Systematic Reviews and Meta-Analyses
Efthymia Prousali, Anna-Bettina Haidich, Andreas Fontalis, Nikolaos Ziakas, Periklis Brazitikos Asimina Mataftsi
This research is co-financed by Greece and the European Union (European Social Fund- ESF)
Myopia is a common visual disorder with increasing prevalence.
Halting progression of myopia is critical, as high myopia can be complicated by a number of vision-compromising conditions.
Forty-four unique primary studies contained in 18 eligible reviews and involving 6400 children were included in the analysis.
Results demonstrated the superior efficacy of atropine eyedrops; 1% atropine vs placebo, 0.025 to 0.05% atropine vs control, 0.01% atropine vs control.
Atropine was followed by orthokeratology (axial elongation: and novel multifocal soft contact lenses.
As regards adverse events, 1% atropine induced blurred near vision (odds ratio [OR] 9.47, [1.17 to 76.78]) and hypersensitivity reactions (OR 8.91, [1.04 to 76.03]).
Existing evidence has failed to convince doctors to uniformly embrace treatments for myopic progression control, possibly due to existence of some heterogeneity, reporting of side effects and lack of long-term follow-up.
Research geared towards efficient interventions is still necessary.